<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434745</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL073980</org_study_id>
    <secondary_id>R01HL073980</secondary_id>
    <nct_id>NCT01434745</nct_id>
  </id_info>
  <brief_title>SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation</brief_title>
  <official_title>Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiving Cholesterol Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if simvastatin improves development and behavior in
      patients with Smith Lemli-Opitz syndrome (SLOS) receiving dietary cholesterol
      supplementation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intellectual quotient (IQ)</measure>
    <time_frame>every 4 months - in person or over the phone assessment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development Quotient (DQ)</measure>
    <time_frame>every 4 months - in person or over the phone assessment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole body cholesterol pool size, synthesis &amp; absorption using stable isotope testing</measure>
    <time_frame>every 4 months, after blood draws</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine markers of sterol metabolism</measure>
    <time_frame>every 4 months, after blood &amp; urine collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent diffusion coefficient (ADC) and fractional anisotopy FA and MRS lipids (brain MRI/MRS)</measure>
    <time_frame>once per year, after MRI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log of response amplitude (electroretinogram)</measure>
    <time_frame>once per year, after ERG</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Smith-Lemli-Opitz Syndrome</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Lactose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5mg/kg/day</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>Lactose will be administered in a capsule formula.</description>
    <arm_group_label>Placebo - Lactose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 1 years old

          -  Subject has confirmed diagnosis of Smith-Lemli-Opitz Syndrome

          -  Subject is currently receiving cholesterol supplementation

        Exclusion Criteria:

          -  Subjects too ill to travel to the study site

          -  Subjects who are unable to safely undergo study procedures

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROBERT STEINER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SHARON BUTCHER, RN</last_name>
    <phone>503-494-6524</phone>
    <email>BUTCHER@OHSU.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SHARON BUTCHER, RN</last_name>
      <phone>503-494-6524</phone>
      <email>BUTCHER@OHSU.EDU</email>
    </contact>
    <investigator>
      <last_name>ROBERT STEINER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Robert Steiner</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>SLOS</keyword>
  <keyword>Cholesterol Supplementation</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cleft Palate</mesh_term>
    <mesh_term>Hypertelorism</mesh_term>
    <mesh_term>Hypospadias</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Smith-Lemli-Opitz Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

